Tokyo, Japan, Dec 20, 2006 - (JCN Newswire) - Takeda Pharmaceutical Company Limited today announced that on December 14, 2006, its wholly owned subsidiary, Takeda Global Research & Development Centre (Europe), Ltd. ("TGRD Europe") received positive opinion from The Committee for Medicinal Products for Human Use ("CHMP") of the European Medicines Agency ("EMEA"), recommending to grant the new indication for ACTOS(R) (pioglitazone HCl).
